Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322821 | 1.00 | KDM4E (0.56) | KDM4ELMNAMEN1KMT2ATSHR | |
| SCHEMBL5239823 | 1.00 | KDM4E (0.56) | KDM4ELMNAMEN1KMT2ATSHR | |
| SCHEMBL5241411 | 1.00 | KDM4E (0.56) | KDM4ELMNAMEN1KMT2ATSHR | |
| SCHEMBL24322617 | 1.00 | KDM4E (0.56) | KDM4ELMNAMEN1KMT2ATSHR | |
| SCHEMBL24322671 | 0.95 | KDM4E (0.54) | KDM4ELMNAMEN1KMT2ATSHR | |
| SCHEMBL13144671 | 0.83 | LMNA (0.47) | KDM4ELMNAMEN1KMT2ATSHR | |
| SCHEMBL24322412 | 0.79 | KDM4E (0.49) | KDM4EMEN1KMT2ASLC6A9NPSR1 | |
| SCHEMBL5241524 | 0.79 | KDM4E (0.49) | KDM4EMEN1KMT2ASLC6A9NPSR1 | |
| SCHEMBL5242798 | 0.79 | KDM4E (0.49) | KDM4ESLC6A9HRH3 | |
| SCHEMBL5241862 | 0.79 | KDM4E (0.49) | KDM4EMEN1KMT2ASLC6A9NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455777-B1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20050267152-A1 | Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders | MDS INC., DOING BUSINESS AS MDS SCIEX (CA) | 2005-12-01 | — | — | US | disclosed |
| WO-2005049023-A1 | GLYT1 TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| EP-1455777-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055478-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267152-A1 | Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders | SLC1A2, SLC1A1, SLC18A2 | KDM4E 3806/4885LMNA 4121/4885MEN1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.